Positivity in biomarkers of amyloid (A+) and tau (T+) was proposed for diagnosing individuals with biologically defined Alzheimer’s disease in a so called A/T/N classification scheme2. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.